Aronson et al. [18] demonstrated a high safety profile of combined therapy with pump and injected insulin Degludec (50% of the basal dose) in adults with T1D who removed their pump before extended periods of exercise. This evidence concerns the gene INS and type 1 diabetes mellitus.